{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:16:36Z","timestamp":1788534996878,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"DOI":"10.1007\/s00595-026-03481-z","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:29:20Z","timestamp":1788532160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarcinoma (BR\u2009+\u2009UR-LA) (CSGO-HBP-008)"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9778-1394","authenticated-orcid":false,"given":"Yoshiteru","family":"Katsura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadafumi","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Nakahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"3481_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.pan.2020.05.020","volume":"20","author":"H Takahashi","year":"2020","unstructured":"Takahashi H, Yamada D, Asukai K, Wada H, Hasegawa S, Hara H, et al. Clinical implications of the serum CA19\u20139 level in biological borderline resectability and biological downstaging in the setting of preoperative chemoradiation therapy for pancreatic cancer. Pancreatology. 2020;20:919\u201328. https:\/\/doi.org\/10.1016\/j.pan.2020.05.020.","journal-title":"Pancreatology"},{"key":"3481_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ags3.12326","volume":"4","author":"H Eguchi","year":"2020","unstructured":"Eguchi H, Kobayashi S, Gotoh K, Noda T, Doki Y. Characteristics of early-onset pancreatic cancer and its association with familial pancreatic cancer and hereditary pancreatic cancer syndromes. Ann Gastroenterol Surg. 2020;4:229\u201333. https:\/\/doi.org\/10.1002\/ags3.12326.","journal-title":"Ann Gastroenterol Surg"},{"key":"3481_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(10)62307-0.","journal-title":"Lancet"},{"key":"3481_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/SLA.0b013e31829b3ce4","volume":"258","author":"H Takahashi","year":"2013","unstructured":"Takahashi H, Ohigashi H, Gotoh K, Marubashi S, Yamada T, Murata M, et al. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013;258:1040\u201350. https:\/\/doi.org\/10.1097\/SLA.0b013e31829b3ce4.","journal-title":"Ann Surg"},{"key":"3481_CR5","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized Phase III PREOPANC trial. J Clin Oncol. 2020;38:1763\u201373. https:\/\/doi.org\/10.1200\/JCO.19.02274.","journal-title":"J Clin Oncol"},{"key":"3481_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/SLA.0000000000000384","volume":"259","author":"JY Jang","year":"2014","unstructured":"Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 2014;259:656\u201364. https:\/\/doi.org\/10.1097\/SLA.0000000000000384.","journal-title":"Ann Surg"},{"key":"3481_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ags3.12418","volume":"5","author":"H Akita","year":"2021","unstructured":"Akita H, Takahashi H, Eguchi H, Asukai K, Hasegawa S, Wada H, et al. Difference between carbohydrate antigen 19\u20139 and fluorine-18 fluorodeoxyglucose positron emission tomography in evaluating the treatment efficacy of neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma: results of a dual\u2010center study. Ann Gastroenterol Surg. 2021;5:381\u20139. https:\/\/doi.org\/10.1002\/ags3.12418.","journal-title":"Ann Gastroenterol Surg"},{"key":"3481_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","volume":"6","author":"V Kunzmann","year":"2021","unstructured":"Kunzmann V, Siveke JT, Alg\u00fcl H, Goekkurt E, Siegler G, Martens U, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:128\u201338. https:\/\/doi.org\/10.1016\/S2468-1253(20)30330-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3481_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(16)00172-8.","journal-title":"Lancet Oncol"},{"key":"3481_CR10","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1245\/s10434-019-07735-8","volume":"26","author":"H Eguchi","year":"2019","unstructured":"Eguchi H, Takeda Y, Takahashi H, Nakahira S, Kashiwazaki M, Shimizu J, et al. A prospective, open-label, multicenter Phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019;26:4498\u2013505. https:\/\/doi.org\/10.1245\/s10434-019-07735-8.","journal-title":"Ann Surg Oncol"},{"key":"3481_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","volume":"5","author":"PA Philip","year":"2020","unstructured":"Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020;5:285\u201394. https:\/\/doi.org\/10.1016\/S2468-1253(19)30327-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3481_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.pan.2023.07.002","volume":"23","author":"R Umezawa","year":"2023","unstructured":"Umezawa R, Mizuma M, Nakagawa K, Yamamoto T, Takahashi N, Suzuki Y, et al. Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel. Pancreatology. 2023;23:650\u20136. https:\/\/doi.org\/10.1016\/j.pan.2023.07.002.","journal-title":"Pancreatology"},{"key":"3481_CR13","doi-asserted-by":"publisher","first-page":"8744","DOI":"10.1245\/s10434-024-16203-x","volume":"31","author":"R Ito","year":"2024","unstructured":"Ito R, Yoshioka R, Yanagisawa N, Ishii S, Sugitani J, Furuya R, et al. Survival analysis of conversion surgery in borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma addressing selection and immortal time bias: a retrospective single-center study. Ann Surg Oncol. 2024;31:8744\u201355. https:\/\/doi.org\/10.1245\/s10434-024-16203-x.","journal-title":"Ann Surg Oncol"},{"key":"3481_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/jhbp.130","volume":"21","author":"H Yanagimoto","year":"2014","unstructured":"Yanagimoto H, Ishii H, Nakai Y, Ozaka M, Ikari T, Koike K, et al. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. J Hepato-bil Pancreat Sci. 2014;21:761\u20136. https:\/\/doi.org\/10.1002\/jhbp.130.","journal-title":"J Hepato-bil Pancreat Sci"},{"key":"3481_CR15","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1200\/JCO.2007.15.8634","volume":"26","author":"DB Evans","year":"2008","unstructured":"Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496\u2013502. https:\/\/doi.org\/10.1200\/JCO.2007.15.8634.","journal-title":"J Clin Oncol"},{"key":"3481_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/MPA.0000000000001231","volume":"48","author":"JM Cloyd","year":"2019","unstructured":"Cloyd JM, Chen HC, Wang X, Tzeng CD, Kim MP, Aloia TA, et al. Chemotherapy versus chemoradiation as preoperative therapy for resectable pancreatic ductal adenocarcinoma: a propensity score adjusted analysis. Pancreas. 2019;48:216\u201322. https:\/\/doi.org\/10.1097\/MPA.0000000000001231.","journal-title":"Pancreas"},{"key":"3481_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1200\/JCO.1985.3.3.373","volume":"3","author":"DJ Klaassen","year":"1985","unstructured":"Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil\u2014an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:373\u20138. https:\/\/doi.org\/10.1200\/JCO.1985.3.3.373.","journal-title":"J Clin Oncol"},{"key":"3481_CR18","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","volume":"29","author":"PJ Loehrer","year":"2011","unstructured":"Loehrer PJ, Sr., Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105\u201312. https:\/\/doi.org\/10.1200\/JCO.2011.34.8904.","journal-title":"J Clin Oncol"},{"key":"3481_CR19","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic Cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 Randomized Clinical Trial. JAMA. 2016;315:1844\u201353. https:\/\/doi.org\/10.1001\/jama.2016.4324.","journal-title":"JAMA"},{"key":"3481_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/bjs.7270","volume":"98","author":"M Bockhorn","year":"2011","unstructured":"Bockhorn M, Burdelski C, Bogoevski D, Sgourakis G, Yekebas EF, Izbicki JR. Arterial en bloc resection for pancreatic carcinoma. Br J Surg. 2011;98:86\u201392. https:\/\/doi.org\/10.1002\/bjs.7270.","journal-title":"Br J Surg"},{"key":"3481_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijrobp.2012.03.059","volume":"85","author":"M Ikeda","year":"2013","unstructured":"Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, et al. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85:163\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.059.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3481_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13014-018-1063-5","volume":"13","author":"Y Goto","year":"2018","unstructured":"Goto Y, Nakamura A, Ashida R, Sakanaka K, Itasaka S, Shibuya K, et al. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Radiat Oncol. 2018;13:118. https:\/\/doi.org\/10.1186\/s13014-018-1063-5.","journal-title":"Radiat Oncol"},{"key":"3481_CR23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","volume":"94","author":"S Krishnan","year":"2016","unstructured":"Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94:755\u201365. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.12.003.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3481_CR24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/MPA.0000000000001140","volume":"47","author":"H Takahashi","year":"2018","unstructured":"Takahashi H, Akita H, Ioka T, Wada H, Tomokoni A, Asukai K, et al. Phase I trial evaluating the safety of preoperative gemcitabine\/nab-paclitaxel with concurrent radiation therapy for borderline resectable pancreatic cancer. Pancreas. 2018;47:1135\u201341. https:\/\/doi.org\/10.1097\/MPA.0000000000001140.","journal-title":"Pancreas"},{"key":"3481_CR25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00595-019-01804-x","volume":"49","author":"H Yoshitomi","year":"2019","unstructured":"Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today. 2019;49:894\u2013906. https:\/\/doi.org\/10.1007\/s00595-019-01804-x.","journal-title":"Surg Today"},{"key":"3481_CR26","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3390\/jcm8111945","volume":"8","author":"T Hank","year":"2019","unstructured":"Hank T, Strobel O. Conversion surgery for advanced pancreatic cancer. J Clin Med. 2019;8:1945. https:\/\/doi.org\/10.3390\/jcm8111945.","journal-title":"J Clin Med"},{"key":"3481_CR27","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djz073","volume":"111","author":"QP Janssen","year":"2019","unstructured":"Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant folfirinox in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111:782\u201394. https:\/\/doi.org\/10.1093\/jnci\/djz073.","journal-title":"J Natl Cancer Inst"},{"key":"3481_CR28","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1007\/s11605-016-3256-2","volume":"20","author":"GP Wright","year":"2016","unstructured":"Wright GP, Poruk KE, Zenati MS, Steve J, Bahary N, Hogg ME, et al. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J Gastrointest Surg. 2016;20:1830\u20135. https:\/\/doi.org\/10.1007\/s11605-016-3256-2.","journal-title":"J Gastrointest Surg"},{"key":"3481_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1245\/s10434-014-3898-9","volume":"22","author":"L Marthey","year":"2015","unstructured":"Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, et al. Folfirinox for locally advanced pancreatic adenocarcinoma: results of an Ageo multicenter prospective observational cohort. Ann Surg Oncol. 2015;22:295\u2013301. https:\/\/doi.org\/10.1245\/s10434-014-3898-9.","journal-title":"Ann Surg Oncol"},{"key":"3481_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/jhbp.547","volume":"25","author":"J Furuse","year":"2018","unstructured":"Furuse J, Shibahara J, Sugiyama M. Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. J Hepato-bil Pancreat Sci. 2018;25:261\u20138. https:\/\/doi.org\/10.1002\/jhbp.547.","journal-title":"J Hepato-bil Pancreat Sci"},{"key":"3481_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/SLA.0000000000001705","volume":"265","author":"S Satoi","year":"2017","unstructured":"Satoi S, Fujii T, Yanagimoto H, Motoi F, Kurata M, Takahara N, et al. Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis. Ann Surg. 2017;265:397\u2013401. https:\/\/doi.org\/10.1097\/SLA.0000000000001705.","journal-title":"Ann Surg"},{"key":"3481_CR32","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s00534-013-0616-0","volume":"20","author":"S Satoi","year":"2013","unstructured":"Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese society of hepato-biliary-pancreatic surgery. J Hepato-bil Pancreat Sci. 2013;20:590\u2013600. https:\/\/doi.org\/10.1007\/s00534-013-0616-0.","journal-title":"J Hepato-bil Pancreat Sci"},{"key":"3481_CR33","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer Zum B\u00fcschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLOS Med. 2010;7:e1000267. https:\/\/doi.org\/10.1371\/journal.pmed.1000267.","journal-title":"PLOS Med"},{"key":"3481_CR34","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/1055-9965.EPI-06-0893","volume":"16","author":"JA Zell","year":"2007","unstructured":"Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev. 2007;16:546\u201352. https:\/\/doi.org\/10.1158\/1055-9965.EPI-06-0893.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3481_CR35","doi-asserted-by":"publisher","first-page":"1510016","DOI":"10.3389\/fonc.2024.1510016","volume":"14","author":"YS Lee","year":"2025","unstructured":"Lee YS, Lee JW, Kim HJ, Chun JW, Lee JC, Jang DK, et al. Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer. Front Oncol. 2025;14:1510016. https:\/\/doi.org\/10.3389\/fonc.2024.1510016.","journal-title":"Front Oncol"},{"key":"3481_CR36","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.21873\/anticanres.16599","volume":"43","author":"M Matsumoto","year":"2023","unstructured":"Matsumoto M, Shirai Y, Uwagawa T, Tsunematsu M, Sakamoto T, Fujioka S, et al. Preoperative therapy for unresectable locally advanced pancreatic cancer for \u2265\u20096 months improves prognosis after pancreatectomy. Anticancer Res. 2023;43:4097\u2013104. https:\/\/doi.org\/10.21873\/anticanres.16599.","journal-title":"Anticancer Res"},{"key":"3481_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","volume":"181","author":"M Ozaka","year":"2023","unstructured":"Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer. 2023;181:135\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2022.12.014.","journal-title":"Eur J Cancer"},{"key":"3481_CR38","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","volume":"270","author":"G Gemenetzis","year":"2019","unstructured":"Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270:340\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000002753.","journal-title":"Ann Surg"},{"key":"3481_CR39","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamasurg.2019.2277","volume":"154","author":"L Maggino","year":"2019","unstructured":"Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154:932\u201342. https:\/\/doi.org\/10.1001\/jamasurg.2019.2277.","journal-title":"JAMA Surg"},{"key":"3481_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","volume":"264","author":"T Hackert","year":"2016","unstructured":"Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264:457\u201363. https:\/\/doi.org\/10.1097\/SLA.0000000000001850.","journal-title":"Ann Surg"},{"key":"3481_CR41","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1245\/s10434-015-4647-4","volume":"22","author":"E Sadot","year":"2015","unstructured":"Sadot E, Doussot A, O\u2019Reilly EM, Lowery MA, Goodman KA, Do RK, et al. Folfirinox induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22:3512\u201321. https:\/\/doi.org\/10.1245\/s10434-015-4647-4.","journal-title":"Ann Surg Oncol"},{"key":"3481_CR42","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00280-018-3554-3","volume":"81","author":"S Yamada","year":"2018","unstructured":"Yamada S, Fujii T, Yokoyama Y, Kawashima H, Maeda O, Suzuki K, et al. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2018;81:815\u201321. https:\/\/doi.org\/10.1007\/s00280-018-3554-3.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-026-03481-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-026-03481-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-026-03481-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:29:26Z","timestamp":1788532166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-026-03481-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":42,"alternative-id":["3481"],"URL":"https:\/\/doi.org\/10.1007\/s00595-026-03481-z","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"interest\n                      .","order":1,"name":"Ethics","label":"Conflict","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}